276 related articles for article (PubMed ID: 2697579)
21. Our experience with interferon alpha: metastatic malignant melanoma.
Merimsky O; Chaitchik S
Mol Biother; 1992 Sep; 4(3):135-8. PubMed ID: 1445667
[TBL] [Abstract][Full Text] [Related]
22. Current therapy for malignant melanoma.
Legha SS
Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
[TBL] [Abstract][Full Text] [Related]
23. Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study.
Stoter G; Aamdal S; Rodenhuis S; Cleton FJ; Iacobelli S; Franks CR; Oskam R; Shiloni E
J Clin Oncol; 1991 Sep; 9(9):1687-91. PubMed ID: 1875225
[TBL] [Abstract][Full Text] [Related]
24. A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma.
Flaherty LE; Redman BG; Chabot GG; Martino S; Gualdoni SM; Heilbrun LK; Valdivieso M; Bradley EC
Cancer; 1990 Jun; 65(11):2471-7. PubMed ID: 2337862
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.
Legha SS; Gianan MA; Plager C; Eton OE; Papadopoulous NE
Cancer; 1996 Jan; 77(1):89-96. PubMed ID: 8630945
[TBL] [Abstract][Full Text] [Related]
26. Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study.
Atzpodien J; Körfer A; Evers P; Franks CR; Knüver-Hopf J; Lopez-Hänninen E; Fischer M; Mohr H; Dallmann I; Hadam M
Mol Biother; 1990 Mar; 2(1):18-26. PubMed ID: 2334534
[TBL] [Abstract][Full Text] [Related]
27. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
[TBL] [Abstract][Full Text] [Related]
29. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group.
Johnson DH; Presant C; Einhorn L; Bartolucci AA; Greco FA
Cancer Treat Rep; 1985; 69(7-8):821-4. PubMed ID: 2410120
[TBL] [Abstract][Full Text] [Related]
31. [Combination of dacarbazine, vindesine and interferon alpha in the treatment of metastatic melanoma].
Mansat-Krzyzanowska E; Dreno B
Ann Dermatol Venereol; 1994; 121(12):884-7. PubMed ID: 7632005
[TBL] [Abstract][Full Text] [Related]
32. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.
Dillman RO; Oldham RK; Barth NM; Birch R; Arnold J; West WH
J Natl Cancer Inst; 1990 Aug; 82(16):1345-9. PubMed ID: 2199682
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of intraperitoneal recombinant interleukin-2 and ex vivo activated intracavitary lymphocytes in patients with malignant peritoneal spread: I. Clinical aspects.
Lurie H; Rakovsky E; Fenig E; Davidovitz J; Adler A
Mol Biother; 1989; 1(3):163-9. PubMed ID: 2604915
[TBL] [Abstract][Full Text] [Related]
34. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
[TBL] [Abstract][Full Text] [Related]
35. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.
Dorval T; Mathiot C; Chosidow O; Revuz J; Avril MF; Guillaume JC; Tursz T; Brandely M; Pouillart P; Fridman WH
Biotechnol Ther; 1992; 3(1-2):63-79. PubMed ID: 1305893
[TBL] [Abstract][Full Text] [Related]
36. Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
Merimsky O; Inbar M; Shiloni E; Ron I; Chaitchik S
Mol Biother; 1990 Dec; 2(4):208-10. PubMed ID: 2288720
[TBL] [Abstract][Full Text] [Related]
37. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
38. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
[TBL] [Abstract][Full Text] [Related]
39. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.
Thatcher N; Dazzi H; Mellor M; Ghosh A; Carrington B; Johnson RJ; Loriaux EM; Craig RP
Br J Cancer; 1990 Apr; 61(4):618-21. PubMed ID: 2331447
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous recombinant interleukin-2 plus chemotherapy with cisplatin and dacarbazine in metastatic melanoma.
Guida M; Latorre A; Mastria A; De Lena M
Eur J Cancer; 1996 Apr; 32A(4):730-3. PubMed ID: 8695281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]